BD Biosciences and StemCell Technologies Sign License Agreements with WARF
Commercialization of Novel Culture Media and Surfaces for Human Embryonic Stem Cell Research
The agreements also mark the beginning of a strategic collaboration between BD Biosciences and StemCell Technologies, which aims to provide products that are superior in quality, performance and reliability to facilitate and support the field of stem cell research. The development of these products arises from primary research performed by Dr. James Thomson and Dr. Tenneille Ludwig at the University of Wisconsin - Madison and the WiCell(TM) Research Institute, a non-profit subsidiary of WARF.
The first commercial products expected from these new license agreements and collaboration are a defined medium and compatible tissue culture surface to support the feeder-independent maintenance of hESC - a major advance in current state-of-the-art cell culture conditions.
Most read news
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.